Search Results

You are looking at 51 - 60 of 1,331 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Cynthia Villarreal-Garza, Fernanda Mesa-Chavez, Alejandra Plata de la Mora, Melina Miaja-Avila, Marisol Garcia-Garcia, Alan Fonseca, Sylvia de la Rosa-Pacheco, Marlid Cruz-Ramos, Manuel Rolando García Garza, Alejandro Mohar, and Enrique Bargallo-Rocha

). Descriptive statistics were used to analyze the sociodemographic and clinicopathologic characteristics of each group. These variables were then compared between groups using a chi-square test. Simple logistic regression using complete-case analysis was

Full access

Alyson Haslam, Jennifer Gill, and Vinay Prasad

anecdotally described, 5 , 6 but in light of the increasing rate of publication in these types of studies, we seek to describe the characteristics of a systematic sampling of NI studies in oncology from an updated search of recent published oncology trials

Full access

Jason H. Lee, Tariq Mohamed, Celia Ramsey, Jihoon Kim, Shelly Kane, Kathryn A. Gold, Farhoud Faraji, and Joseph A. Califano III

association of patient, provider, and treatment team characteristics, including 1- or 2-month deadline, with the prevalence of and time to staging. Patient characteristics included age, sex, race, and Charlson comorbidity index (CCI) score. Provider

Full access

Mohammed W. Rahman, Niti U. Trivedi, Peter B. Bach, and Aaron P. Mitchell

Characteristics The proportion of oncologists who received any payments within the year increased from 65.1% in 2014 to 68.7% in 2017, and the proportion who received >$10,000 within the year increased from 7.0% to 10.2% ( Table 2 ). In comparison, in 2014, 44

Full access

Ning Ning, Jingsheng Yan, Xian-Jin Xie, and David E. Gerber

following characteristics: year, disease under study, phase and type (interventional/noninterventional), and sponsor type (institutional/industrial). Institutional trials included investigator-initiated trials with a local study chair or a study chair at

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

were extracted from ClinicalTrials.gov . Of these, 500 did not meet inclusion criteria, most because they did not use a drug intervention (80%; 400/500). Trials may have been excluded for more than one reason ( Figure 1 ). Characteristics of the 215

Full access

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

backward selection of variables at a significance level of P <.10. An alpha threshold of 0.05 was chosen for statistical significance. Statistical analyses were performed using SPSS Statistics, version 24.0 (IBM Corp). Results Patient Characteristics A

Full access

Vinayak Muralidhar, Paul J. Catalano, Gally Reznor, Brandon A. Mahal, Toni K. Choueiri, Christopher J. Sweeney, Neil E. Martin, Clair J. Beard, Yu-Wei Chen, Michelle D. Nezolosky, Karen E. Hoffman, Felix Y. Feng, Quoc-Dien Trinh, and Paul L. Nguyen

, treatment, and survival data in addition to patient-specific demographic characteristics, covering 28% of the US population and 97% of incident cancers. 12 SEER was linked to Medicare administrative data, which contains insurance claims data for patients

Full access

Ami M. Vyas, Hilary Aroke, and Stephen Kogut

explained portion of the gap is the sum of the differences between HR-positive and HR-negative women in terms of observed characteristics weighted by the pooled regression coefficients. It is calculated by multiplying the differences in the average

Full access

Iman K. Berrahou, Ava Snow, Megan Swanson, and Juno Obedin-Maliver

selected because of their particular relevance to the SGM population with regard to enumeration of protections in nondiscrimination policies across federal and state laws. Analyses were performed to determine whether cancer center characteristics impacted